Causation
A Rare Clinical Presentation of Malignant Pleural Mesothelioma With Central Nervous System Metastases: A Case Report
Cureus 2025 September 14 [Link] Magdalena A Miernik-Skrzypczak, Elwira Misztela-Lisiecka, Piotr Nowakowski, Anna Strozak, Grazyna Waska Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the pleural mesothelial cells, most often associated with long-term asbestos exposure. Symptoms are typically nonspecific, including shortness of breath, chest pain, and pleural effusion, which may…
Read MoreApical Malignant Pleural Mesothelioma Presenting as Horner’s Syndrome: A Case Report
Cureus 2025 October 13 [Link] Shruthi Mankal, Chris Jacobs Abstract Horner’s syndrome is a well-recognized presentation of apical lung tumors, though rarely associated with malignant pleural mesothelioma (MPM), with only a few cases documented. We report the case of an 82-year-old man with persistent right-sided chest pain who developed unilateral right-sided ptosis, miosis and a…
Read MoreThe role of non-coding RNAs in pleural mesothelioma
Translational Oncology 2025 September 29 [Link] Giulia Tonnini, Giulia Di Mauro, Maria Letizia Tramarin, Anna Meneghetti, Ilaria Bononi, Chiara Mazziotta, John Charles Rotondo, Elisa Mazzoni, Maria Rosa Iaquinta, Elisabetta Trabetti, Cristina Bombieri, Monica De Mattei, Mauro Tognon, Fernanda Martini Abstract Background: Pleural mesothelioma (PM) is a rare and highly aggressive tumor, primarily caused by asbestos…
Read MoreLong-term survival of nonoccupational pleural mesothelioma: a case report and review of the literature
Journal of Medical Case Reports 2025 October 21 [Link] Loreta Tobia, Elio Tolli, Adalgisa Ilaria Sedile, Vincenza Cofini, Stefano Necozione, Leila Fabiani Abstract Introduction: Malignant mesothelioma is an aggressive cancer that arises from the mesothelial cells lining the pleura, peritoneum, pericardium, or tunica vaginalis. While occupational exposure accounts for most cases, nonoccupational exposures (to ionizing…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreFibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma
Radiology and Oncology 2025 June 16 [Link] Katja Adamic, Mateja Marc Malovrh, Urska Bidovec Stojkovic, Ales Rozman Abstract Background: Malignant pleural mesothelioma (MPM) is a global health concern linked to asbestos exposure. In Slovenia, regions with high asbestos exposure rates make MPM a significant public health issue. Although thoracoscopic biopsy is the gold standard for…
Read MoreImmune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma
Frontiers in Pharmacology 2025 May 23 [Link] Lin Shi, Dongqi Yuan, Fuyi Zhu, Yuchao He, Ran Zuo, Liwei Chen, Yi Luo, Yu Wang, Dingzhi Huang, Peng Chen, Hua Guo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure. Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic…
Read MoreBAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
Cancers 2025 May 6 [Link] Susana Cedres, Augusto Valdivia, Ilaria Priano, Pedro Rocha, Patricia Iranzo, Nuria Pardo, Alex Martinez-Marti, Enriqueta Felip Abstract Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy…
Read MoreUnraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Investigational New Drugs 2025 May 8 [Link] Gregorio Bonsignore, Elia Ranzato , Simona Martinotti Abstract Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body’s serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM’s prevalence. PM has a long latency period, making major…
Read MoreOncological Outcomes Of Radical Surgery With And Without Induction And Adjuvant Chemotherapy In Mesothelioma Patients – 8-Year Experience In A Single Center
Portuguese Journal of Cardiac Thoracic & Vascular Surgery 2025 April 29 [Link] Agata Nawojowska, Samuel Mendes, Marion Gaspar, Daniel Cabral, Cristina Rodrigues, Mariana Antunes, Magda Alvoeiro, Telma Calado, Francisco Félix Abstract Introduction: Mesothelioma is a devastating, insidious disease with a long latency period. Its peak incidence occurs in the 5th and 6th decades of life,…
Read More